Therapeutics: Receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1)

In vitro and mouse studies suggest ponatinib-based RIPK1 inhibitors could help treat inflammatory diseases. In vitro screening of kinase inhibitors showed ponatinib inhibited RIPK1 with an IC50 of 12 ...